Novartis AG (NVS) Latest Company News

Sep 4, 2026, 21:20 UTC
Ionis Pharmaceuticals and partner Novartis announced on Friday that their experimental heart drug failed in a late-stage trial.
Source:
- reuters.com
Sep 4, 2026, 21:07 UTC
Novartis announced that its experimental cardiovascular drug pelacarsen failed to reduce cardiovascular risk in the Phase 3 HORIZON trial.
Source:
Sep 2, 2026, 12:37 UTC
Novartis plans to cease production at its Kleinhüningen site in Basel, potentially eliminating about 130 jobs, subject to information and consultation procedures.
Source:
Sep 2, 2026, 12:12 UTC
South Korea's Alteogen signed a deal with Swiss drugmaker Novartis worth up to $3.22 billion, granting Novartis access to Alteogen's technology for making injectable versions of intravenous drugs.
Source:
Sep 1, 2026, 07:13 UTC
Novartis announced that its oral drug remibrutinib met the main goals in two late-stage studies, showing superiority over a rival drug in reducing relapse rates in patients with a form of multiple sclerosis.
Source:
Sep 1, 2026, 04:14 UTC
Novartis paused eight clinical trials of an experimental cell therapy for autoimmune and neurological disorders in late August 2026 after three patient deaths.
Source:
Aug 29, 2026, 07:32 UTC
Novartis presented Phase 2 TRANQUILITY study results at the European Society of Cardiology annual meeting in Munich, showing its drug pacibekitug reduced inflammation biomarkers in a dose-dependent manner.
Source:
- statnews.com
Aug 28, 2026, 00:18 UTC
China's National Healthcare Security Administration held a symposium on August 27, 2026, with 16 pharmaceutical companies to discuss industry development and gather opinions for the 15th Five-Year Plan period.
Source:
- finance.sina.cn
Aug 25, 2026, 13:43 UTC
Novartis announced that China's National Medical Products Administration (NMPA) approved its radioligand therapy drug Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for a new indication in metastatic hormone-sensitive prostate cancer patients.
Source:
- finance.sina.cn
Aug 18, 2026, 13:25 UTC
Novartis announced it will not pursue reimbursement in Canada for Vanrafia, its newly approved treatment for a rare kidney disease, due to the current access environment.
Source:
- statnews.com
Aug 18, 2026, 12:23 UTC
On August 18, 2026, Yingte Group and Hangzhou PICC signed a strategic cooperation agreement to jointly launch a provincial exclusive specialty drug commercial insurance product called 'Yingte-PICC Yao Kangbao'.
Source:
- finance.sina.cn
Aug 13, 2026, 13:56 UTC
Novartis defeated a UK court bid by Accord Healthcare to invalidate its patent for the heart drug Entresto, with London's High Court rejecting the claim.
Source:
- reuters.com
Aug 10, 2026, 15:11 UTC
The U.S. Food and Drug Administration rejected ITM Isotope Technologies Munich SE's radiopharmaceutical therapy ITM-11 due to manufacturing issues, preventing it from becoming a competitor to Novartis' treatment.
Source:
- statnews.com
- statnews.com
Aug 4, 2026, 21:33 UTC
Swiss pharmaceutical company Novartis announced a $23 billion investment in 10 different U.S. manufacturing and research & development facilities, creating 4,000 jobs.
Source:
- whitehouse.gov
- conservativehq.com
Aug 3, 2026, 17:46 UTC
The Swiss Market Index (SMI) closed marginally up on Monday, with Logitech International and Sonova leading gains, while Sandoz Group and Holcim declined.
Source:
- finanzen.at
- rttnews.com
Jul 31, 2026, 20:26 UTC
Novartis announced that its drug Pluvicto received FDA approval for PSMA-positive metastatic hormone-sensitive prostate cancer, potentially advancing a new standard of care for metastatic prostate cancer.
Source:
- finance.sina.cn
Jul 31, 2026, 14:13 UTC
Novartis's sacubitril/valsartan sodium tablets were selected in the 12th batch of China's national centralized drug procurement, covering the heart failure indication.
Source:
- finance.sina.cn
- finance.sina.cn
Jul 30, 2026, 13:00 UTC
The Arkansas State Board of Pharmacy voted on July 30, 2026 to suspend enforcement of Act 630 of 2025, a law that would have prevented drugmakers from limiting which pharmacies can purchase their drugs, after a federal judge ruled the law unconstitutional.
Source:
- magnoliareporter.com
Jul 21, 2026, 05:00 UTC
Novartis AG reported second-quarter core earnings per share of $2.41 and net sales of $14.41 billion.
Source:
Jul 17, 2026, 19:26 UTC
Novartis receives full FDA approval for Fabhalta in IgA nephropathy.
Source:
- zacks.com
Jul 16, 2026, 12:00 UTC
Novartis promoted Pankhuri Garg to director of talent and development, effective immediately.
Source:
- hrkatha.com
Jul 15, 2026, 05:00 UTC
Chai Discovery announced a collaboration agreement with Novartis.
Source:
- techfundingnews.com
Jul 6, 2026, 05:05 UTC
Novartis has agreed to acquire Myricx Bio for up to $1.5 billion.
Source:
Jun 30, 2026, 22:45 UTC
Novartis and Antares have signed an agreement for cancer small molecules.
Source:
- cen.acs.org

← PreviousPage 2Next →

NVS

Ionis Pharmaceuticals and partner Novartis announced on Friday that their experimental heart drug failed in a late-stage trial.

Novartis announced that its experimental cardiovascular drug pelacarsen failed to reduce cardiovascular risk in the Phase 3 HORIZON trial.

Novartis plans to cease production at its Kleinhüningen site in Basel, potentially eliminating about 130 jobs, subject to information and consultation procedures.

South Korea's Alteogen signed a deal with Swiss drugmaker Novartis worth up to $3.22 billion, granting Novartis access to Alteogen's technology for making injectable versions of intravenous drugs.

Novartis announced that its oral drug remibrutinib met the main goals in two late-stage studies, showing superiority over a rival drug in reducing relapse rates in patients with a form of multiple sclerosis.

Novartis paused eight clinical trials of an experimental cell therapy for autoimmune and neurological disorders in late August 2026 after three patient deaths.

Novartis presented Phase 2 TRANQUILITY study results at the European Society of Cardiology annual meeting in Munich, showing its drug pacibekitug reduced inflammation biomarkers in a dose-dependent manner.

China's National Healthcare Security Administration held a symposium on August 27, 2026, with 16 pharmaceutical companies to discuss industry development and gather opinions for the 15th Five-Year Plan period.

Novartis announced that China's National Medical Products Administration (NMPA) approved its radioligand therapy drug Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for a new indication in metastatic hormone-sensitive prostate cancer patients.

Novartis announced it will not pursue reimbursement in Canada for Vanrafia, its newly approved treatment for a rare kidney disease, due to the current access environment.

On August 18, 2026, Yingte Group and Hangzhou PICC signed a strategic cooperation agreement to jointly launch a provincial exclusive specialty drug commercial insurance product called 'Yingte-PICC Yao Kangbao'.

Novartis defeated a UK court bid by Accord Healthcare to invalidate its patent for the heart drug Entresto, with London's High Court rejecting the claim.

The U.S. Food and Drug Administration rejected ITM Isotope Technologies Munich SE's radiopharmaceutical therapy ITM-11 due to manufacturing issues, preventing it from becoming a competitor to Novartis' treatment.

Swiss pharmaceutical company Novartis announced a $23 billion investment in 10 different U.S. manufacturing and research & development facilities, creating 4,000 jobs.

The Swiss Market Index (SMI) closed marginally up on Monday, with Logitech International and Sonova leading gains, while Sandoz Group and Holcim declined.

Novartis announced that its drug Pluvicto received FDA approval for PSMA-positive metastatic hormone-sensitive prostate cancer, potentially advancing a new standard of care for metastatic prostate cancer.

Novartis's sacubitril/valsartan sodium tablets were selected in the 12th batch of China's national centralized drug procurement, covering the heart failure indication.

The Arkansas State Board of Pharmacy voted on July 30, 2026 to suspend enforcement of Act 630 of 2025, a law that would have prevented drugmakers from limiting which pharmacies can purchase their drugs, after a federal judge ruled the law unconstitutional.

Novartis AG reported second-quarter core earnings per share of $2.41 and net sales of $14.41 billion.

Novartis receives full FDA approval for Fabhalta in IgA nephropathy.

Novartis promoted Pankhuri Garg to director of talent and development, effective immediately.

Chai Discovery announced a collaboration agreement with Novartis.

Novartis has agreed to acquire Myricx Bio for up to $1.5 billion.

Novartis and Antares have signed an agreement for cancer small molecules.